phrykt

Standard Biotools Inc. (LAB): who owns it and who trades it

As of Nov 16, 2026, LAB insiders reported 10 purchases worth $12.2M in the last 12 months. The largest buyer was Casdin Partners GP, LLC (Director), with $10M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Standard Biotools

From the latest filings

Overall: more buying than selling. Insiders mostly bought. Funds and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns LAB

144 funds and institutions reported LAB shares worth $245M at the end of Q2 2026, about 76% of the company. The largest holder is Casdin Capital, LLC with 22.8%.

Funds and institutions (13F) 76%Everyone else 24%

10 largest owners, by share of the company

Casdin Capital, LLC22.8%
Viking Global Investors LP15.0%
Mak Capital One LLC7.4%
Long Focus Capital Management, LLC6.0%
Vanguard Capital Management LLC3.1%
BlackRock, Inc.2.1%
Hollow Brook Wealth Management LLC1.4%
Neuberger Berman Group LLC1.3%
Qube Research & Technologies Ltd1.2%
Royce & Associates LP1.2%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Casdin Capital, LLC88.78M22.76%$73MNo change
Viking Global Investors LP58.65M15.04%$48.3MNo change
Mak Capital One LLC28.81M7.39%$23.7M+10%
Long Focus Capital Management, LLC23.50M6.02%$19.3M+47%
Vanguard Capital Management LLC12.25M3.14%$10.1M-4%
BlackRock, Inc.8.25M2.12%$6.8M-67%
Hollow Brook Wealth Management LLC5.50M1.41%$4.5M-3%
Neuberger Berman Group LLC4.96M1.27%$4M+6%
Qube Research & Technologies Ltd4.82M1.24%$4M+584%
Royce & Associates LP4.53M1.16%$3.7M+51%
Geode Capital Management, LLC3.90M1.00%$3.2M-47%
Tikvah Management LLC3.55M0.91%$2.9MNo change
Millennium Management LLC3.51M0.90%$2.9M+67%
Morgan Stanley2.83M0.73%$2.3M-2%
D. E. Shaw & Co., Inc.2.82M0.72%$2.3M+1315%
Jane Street Group, LLC2.51M0.64%$2.1M–
Peapod Lane Capital LLC2.41M0.62%$2M+19%
Citadel Advisors LLC2.35M0.60%$1.9M+92%
Mink Brook Asset Management LLC2.19M0.56%$1.8M–
Sone Capital Management, LLC2.13M0.55%$1.8M+21%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, LAB insiders reported $12.2M of open-market purchases and $0 of sales.

Purchases, 12 months
$12.2M
10 trades, 5 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Nov 5, 2026
Filed Nov 5, 2026

Purchases and sales by month

$503K$503KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 5, 2026Thomas D. CareyDirectorPurchase75,000$0.63$46.9KForm 4
Dec 4, 2025Casdin Private Growth Equity Fund Gp, Llc +7DirectorPurchase150,000$1.45$218KForm 4
Dec 3, 2025Casdin Private Growth Equity Fund Gp, Llc +7DirectorPurchase75,000$1.44$108KForm 4
Dec 2, 2025Casdin Private Growth Equity Fund Gp, Llc +7DirectorPurchase125,000$1.42$178KForm 4
Nov 25, 2025Casdin Partners GP, LLC +7DirectorPurchase7.55M$1.30$9.8MForm 4
Nov 24, 2025Casdin Partners GP, LLC +7DirectorPurchase150,000$1.43$214KForm 4
Nov 20, 2025Eli Casdin +7DirectorPurchase450,000$1.30$585KForm 4
Nov 19, 2025Eli Casdin +7DirectorPurchase350,000$1.28$448KForm 4
Nov 18, 2025Eli Casdin +7DirectorPurchase275,000$1.23$338KForm 4
Nov 17, 2025Casdin Partners Master Fund, L.P. +7DirectorPurchase225,000$1.22$274KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Casdin Partners GP, LLCDirector, 10% owner$10M–Nov 25, 2025
Eli CasdinDirector, 10% owner$1.4M–Nov 20, 2025
Casdin Private Growth Equity Fund Gp, LlcDirector$503K–Dec 4, 2025
Casdin Partners Master Fund, L.P.Director, 10% owner$274K–Nov 17, 2025
Thomas D. CareyDirector$46.9K–Nov 5, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

LAB short interest

Low short interest. 0.6% of LAB shares are sold short: about 1 share in 181. Over the last 12 reports the number of shares short went down 83%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 2.17M LAB shares were sold short, 0.6% of the shares outstanding, down 11.3% from the report before. At the average daily volume of 706,767 shares, buying them all back would take about 3.1 trading days (days to cover).

Shares short, % of all shares

0.55%May 15Oct 303.79%

Days to cover

3.1May 15Oct 307.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.17M0.55%-11%706,7673.1
Oct 15, 20262.45M0.62%-3%979,9062.5
Sep 30, 20262.52M0.64%-3%925,4912.7
Sep 15, 20262.59M0.66%-13%1.80M1.4
Aug 31, 20262.98M0.76%+24%1.70M1.8
Aug 14, 20262.41M0.61%-11%1.11M2.2
Jul 31, 20262.69M0.69%+22%2.02M1.3
Jul 15, 20262.21M0.57%-35%3.06M1.0
Jun 30, 20263.43M0.88%-66%6.85M1.0
Jun 15, 202610.03M2.57%-24%4.95M2.0
May 29, 202613.13M3.37%+2%2.22M5.9
May 15, 202612.92M3.31%+9%1.85M7.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Standard Biotools company events

Standard Biotools filed 16 reports on Form 8-K in the last 12 months, 6 of them about an important change (leadership, control, listing). The latest was on Nov 3, 2026.

  1. Nov 3, 2026AnnouncementShared information with investors. Filing
  2. Oct 5, 2026AnnouncementShared information with investors. Filing
  3. Sep 30, 2026AgreementAs previously disclosed, on July 28, 2026, Standard BioTools Inc., a Delaware corporation, entered into a Share and Asset Purchase Agreement with Multiplex Bio Inc., a Delaware corporation, pursuant to which Multiplex Bio agreed to acquire the mass cytometry business of the Company. Filing
  4. Aug 5, 2026ResultsReleased financial results. Filing
  5. Jul 28, 2026AgreementStandard BioTools Inc., a Delaware corporation, entered into a Termination, Waiver and Release Agreement with Illumina, Inc., a Delaware corporation. Filing
  6. Jul 24, 2026ListingStandard BioTools Inc. (NASDAQ: LAB) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the Company did not meet the minimum bid price requirement set forth in Nasdaq’s Listing Rules for continued listing on The Nasdaq Global… Filing
  7. Jun 18, 2026LeadershipStandard BioTools Inc. held its 2026 Annual Meeting of Stockholders on June 17, 2026. Filing
  8. Jun 8, 2026ControlTo the extent required by this Item, the information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. Filing
  9. Jun 5, 2026AnnouncementStandard BioTools Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that it has regained compliance with Nasdaq Listing Rule 5450(a)(1). Filing
  10. Jun 3, 2026LeadershipThe Human Capital Committee of the Board of Directors of Standard BioTools Inc. approved a grant of 500,000 restricted stock units for Sean Mackay, Chief Business Officer of the Company, under the Company’s 2026 Equity Incentive Plan, effective as of June 20, 2026. Filing
  11. May 28, 2026LeadershipThe Board of Directors of Standard BioTools Inc. approved the Company’s 2026 Change of Control and Severance Plan and Participation Agreement thereunder. Filing
  12. May 5, 2026ResultsReleased financial results. Filing
  13. Apr 24, 2026ListingStandard BioTools Inc. (NASDAQ: LAB) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the Company did not meet the minimum bid price requirement set forth in Nasdaq’s Listing Rules for continued listing on The Nasdaq Global… Filing
  14. Feb 24, 2026ResultsReleased financial results. Filing
  15. Jan 30, 2026DealStandard BioTools Inc., a Delaware corporation completed the previously announced sale of all of the equity interests of SomaLogic, Inc., Sengenics Corporation LLC and Sengenics Corporation Pte Ltd (such equity interests, collectively, the “ Shares ”), the entities that operate the Company’s… Filing
  16. Jan 8, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Standard Biotools financials

Famous investors that hold LAB

5 of the 50 well-known investors we track reported holding LAB in their latest 13F filing. The largest position is Andreas Halvorsen's, worth $43.4M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Andreas Halvorsen · Viking Global InvestorsQ3 202658.65M$43.4M0.1%No change
Ken Griffin · Citadel AdvisorsQ3 20262.57M$1.9M0.0%+9%
Jim Simons · Renaissance TechnologiesQ3 20262.04M$1.5M0.0%+106%
Israel Englander · Millennium ManagementQ3 2026532,466$394K0.0%-85%
Steve Cohen · Point72 Asset ManagementQ3 2026104,678$77.5K0.0%-85%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named LAB in the last 120 days.

FiledHolderFormStake
Nov 16, 2026MAK Capital Fund LP13G/A6.3%
Nov 16, 2026MAK Capital Fund LP13G/A6.3%

Questions about Standard Biotools Inc. (LAB) stock

Who owns the most LAB stock?

The largest reported owner of Standard Biotools Inc. (LAB) is Casdin Capital, LLC, with 22.8% of the company. In total, 144 funds and institutions reported holding LAB at the end of Q2 2026, together about 76% of the shares. See the largest owners.

Are LAB insiders buying or selling?

In the last 12 months, LAB insiders reported 10 open-market purchases worth $12.2M and no sales. The latest trade was on Nov 5, 2026. See every trade.

What is the short interest in LAB?

As of Oct 30, 2026, 2.17M LAB shares were sold short, 0.6% of the shares outstanding, down 11.3% from the report before. At the average daily volume of 706,767 shares, buying them all back would take about 3.1 trading days (days to cover). See the history.

Which famous investors hold LAB?

5 of the 50 well-known investors we track reported LAB in their latest 13F filing, including Andreas Halvorsen, Ken Griffin, Jim Simons. The largest position is worth $43.4M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.